Monitoring Blood Clearance of Nucleosome and CTCF During Surgery for Peritoneal Metastases from Colorectal Cancer

What this Trial Is About

Colorectal cancer is a common disease in France, often spreading to the liver, lungs, and peritoneum. For patients with moderate peritoneal metastases, cytoreductive surgery is usually recommended at specialized centers. After surgery, doctors use a score called the CC-Score to evaluate how completely the tumor was removed, but this is a subjective measure. The study aims to explore new biological markers, such as circulating tumor DNA and markers related to epigenetic changes, to develop an objective score for detecting leftover disease after surgery. Participants will undergo blood sampling at multiple time points, from before surgery through 4 to 6 weeks after the procedure, to monitor the levels and clearance of nucleosomes and the transcription factor CTCF. The study includes different patient groups, including those with peritoneal metastases from colorectal cancer, colorectal cancer without metastases, non-oncological chronic inflammatory diseases, and non-malignant abdominal conditions. The blood samples will help understand how these markers change around surgery and how they relate to inflammation and residual disease. During the study, participants will have blood taken at baseline, during surgery, and multiple times post-surgery up to 6 weeks later. Researchers will measure the kinetics of nucleosomes, CTCF, and inflammatory markers like albumin, C-reactive protein, and interleukin IL-6. They will analyze how these markers correlate and evaluate their accuracy in detecting residual disease. The total study period for each participant covers up to 4 to 6 weeks after surgery, with close monitoring of biological markers and inflammation.

Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.